PharmaTelevision - Phylogica: Business Strategy of Australian Biotech

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Phylogica: Business Strategy of Australian Biotech

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this exclusive interview, Fintan Walton talks to Dr Stewart Washer, CEO of Phylogica, about the company’s research using its peptide-based drug discovery technology platform. He discusses the challenges faced by an Australian preclinical-stage biotech in obtaining funding, and how Phylogica’s business model aims to do this through both equity financing and deals with other companies. Dr Washer talks about Phylogica’s current collaborations with Johnson & Johnson Research and with Opsona, and how he believes that the interest of bigger pharmas in Phylogica will grow once the company’s compounds are in Phase I/IIa clinical development. Finally, he discusses how Phylogica’s strategy also includes gaining complementary technologies – both disease targets in the area of inflammation and drug delivery technologies – through acquisitions and partnerships.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Peptide based drug discovery technology platform and its specific targets

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here live in Brisbane. On this show I have Stewart Washer, who is CEO of Phylogica , welcome to the show Stewart.

Stewart Washer:

Thanks Fintan Walton.

Fintan Walton:

Stewart Washer, you've been on the show before and we've covered Phylogica now over several years and you are no longer a startup company, you are a maturing biotech in Eastern Australian terms?

Stewart Washer:

Yes.

Fintan Walton:

Listed on the ASX and your company has a specific platform technology, I am gonna call it a platform technology which has product development capabilities?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Stewart Washer

CEO

Dr. Stewart Washer is CEO of the Australian company Phylogica. He has over 12 years' experience in the biotechnology industry, as well as extensive international capital market experience, and has raised over $38 M in private shareholder and government funds. Before his appointment at Phylogica , Dr Stewart Washer was CEO of Celentis, where he managed the commercialization of IP from the largest Crown Research Institute in New Zealand (AgResearch). During this time, and before this when he was based in Australia, Dr Stewart Washer formed and governed a number of successful biotechnology companies.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Phylogica

Phylogica is an Australian biotechnology company engaged in the discovery and development of novel biopharmaceuticals directed at proteins and their interactions. Its proprietary technologies (Phylomer-peptide-libraries and the Blocker Trap tool used for Phylomer selection) originate from a close collaboration between the Telethon Institute for Child Health Research in Perth, Western Australia and The Fox Chase Cancer Center in Philadelphia, US, which were responsible for founding Phylogica in 2001. These technologies are currently being applied to the development of drugs for the treatment of inflammatory diseases, including asthma, stroke and diabetes.